Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity

• Published in: Journal for immunotherapy of cancer Vol. 8; no. 1; p. e000266
• Main Authors: Reches, Adi, Ophir, Yael, Stein, Natan, Kol, Inbal, Isaacson, Batya, Charpak Amikam, Yoav, Elnekave, Afek, Tsukerman, Pinchas, Kucan Brlic, Paola, Lenac, Tihana, Seliger, Barbara, Jonjic, Stipan, Mandelboim, Ofer
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.06.2020; BMJ Publishing Group
• Subjects: Animals; Antibodies; Cancer; Cell Adhesion Molecules - metabolism; Cytokines; Experiments; Female; Histograms; Humans; Immunotherapy; Immunotherapy - methods; Immunotherapy Biomarkers; Ligands; Mice; Proteins; Receptors, Immunologic - metabolism; immunology

BackgroundThe use of checkpoint inhibitors has revolutionized cancer therapy. Unfortunately, these therapies often cause immune-related adverse effects, largely due to a lack of tumor specificity.MethodsWe stained human natural killer cells using fusion proteins composed of the extracellular portion...